Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation

7Citations
Citations of this article
37Readers
Mendeley users who have this article in their library.

Abstract

The chimeric antigen receptor T (CAR-T) cells play an antileukemia role, and can be used to treat or prevent relapse by targeting minimal residual disease for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the infusion of allogeneic CAR-T cells may also cause graft-versus-host disease, which limited their applications during and after allo-HSCT. In this review, we discuss the clinical trials that applying CAR-T cells before allo-HSCT and the use of donor-derived CAR-T cells as conditioning regimen during allo-HSCT. At last, we analyzed the effect of donor-derived CAR-T cells on preventive infusion after allo-HSCT.

Cite

CITATION STYLE

APA

Liu, J., Zhang, X., Zhong, J. F., & Zhang, C. (2019). Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation. Immunotherapy, 11(1), 37–44. https://doi.org/10.2217/imt-2018-0089

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free